Vermillion Inc (VRML.OQ) Quote| Reuters.com
Edition:
United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.10USD
1 Jul 2016
Change (% chg)

$-0.01 (-0.90%)
Prev Close
$1.11
Open
$1.12
Day's High
$1.12
Day's Low
$1.10
Volume
959
Avg. Vol
8,300
52-wk High
$2.29
52-wk Low
$1.00

VRML.OQ

Chart for VRML.OQ

About

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $57.33
Shares Outstanding(Mil.): 52.12
Dividend: --
Yield (%): --

Financials

  VRML.OQ Industry Sector
P/E (TTM): -- 42.29 36.15
EPS (TTM): -0.40 -- --
ROI: -141.35 -6.23 14.31
ROE: -141.63 -5.61 15.51

BRIEF-Vermillion Inc Q1 loss per share $0.09

* Expect net cash utilization of $2.0 million - $3.0 million in q2 of 2016

May 16 2016

BRIEF-Vermillion announces publication of first ova1 clinical utility study

* Vermillion announces publication of first ova1 clinical utility study

Apr 19 2016

BRIEF-Vermillion receives $2 mln disbursement of up to $4 mln loan

* Vermillion receives $2 million disbursement of up to $4 million loan from the connecticut department of economic and community development

Apr 18 2016

BRIEF-Vermillion Q4 loss per share $0.10

* Vermillion reports fourth quarter and full year 2015 results Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Mar 24 2016

BRIEF-Vermillion announces FDA clearance of Overa, second generation Ova1 test

* Vermillion announces FDA clearance of Overa, second generation Ova1 test Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Mar 21 2016

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $39.54 +0.23
Becton Dickinson and Co (BDX.N) $169.64 +0.05
Arrayit Corp (ARYC.PK) $0.00 --
Pfizer Inc. (PFE.N) $35.57 +0.36

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.